Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3
17 May 2025 (08:00 - 12:45)
Organised by: 
About the speaker
National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)
3 More presentations in this session
Doctor M. Pepin (Stanford, US)
Miss K. Kohlat (German Heart Center Of Charite Berlin, DE)
Access the full session
The Event
Heart Failure 2025
17 May - 20 May 2025
You may be interested in
Congress Session
